AEMD - Earnings call 4 2021 | Aethlon Medical, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Aethlon Medical Fiscal 2021 Year-End Earnings and Corporate Update Conference Call. [Operator Instructions]. Please note, this event is being recorded.

I would now like to turn the conference over to Jim Frakes, Chief Financial Officer. Please go ahead.

James Frakes

good and operator, you, afternoon, everyone. Thank Aethlon to Medical's Fiscal Call. Conference Earnings XXXX Year-end Welcome Jim I Frakes, Financial is name My and Officer. am Chief Aethlon's At X:XX p.m. fiscal Aethlon results ended today, released XX, year-end its March Time year -- Eastern XXXX. fiscal Medical for financial

Aethlon not the please at received page earnings release, If you or Medical's have www.aethlonmedical.com. seen visit Investors

remarks and and of Fisher, brief our introduction an overview Aethlon's recent provide make will I on of statement, then Aethlon's this Following strategy forward-looking the reading Aethlon's developments. will Chuck CEO, financials. Dr. some

We open session. the for call will up then the Q&A

statements Act please I that this forward-looking you in a cautions These call. as call Before the statement statements. within Federal the the over statement from date statement. of of hand and any anticipated may forward-looking the that Exchange of risks differ actual statements contain news to the is materially results and XXXX. forward-looking Dr. today are forward-looking The Act subject not Fisher, is historical conference of the assumptions and Securities note fact on company expectations release meaning that and statements uncertainties, of are results the of this XXXX and call the Securities to significant a based Such

March report Securities cause annual Factors Commission. filings with XXXX, on found forward-looking our statements Form company's under and other from for to can XX, results in that company's on those XX-Q XX-K could fiscal and be in most Factors the materially differ anticipated the ended year the the in recent caption report the Exchange Risk

update or it nor does company reflect the future undertake events law, intend circumstances. by required be to may any to duty information as does this Except not

to Fisher, turn Financial will the Medical's CEO. call now Chief I that, Dr. Chuck over Officer -- Aethlon With

Charles Fisher

dialing you, Jim, of thank in. you for and all Thank

where and Chuck on of afternoon. you name the and/or good I'm morning Medical. are, Fisher, My depending good CEO So is Aethlon

was which this at worked almost of SARS-CoV-X, start a know of agent on for COVID-XX, Aethlon bind SARS SARS-CoV-X, virus, glycosylated, The viruses, includes been virus. annotation like causing demonstrated original Hemopurifier coated. that with and is all from all remove is some which patient. has it's including you means point, SARS MERS to off from coronavirus circulation sugar is basics. blood to CoV a the like coronaviruses, member family, as ago. removal a I'd and SARS-CoV-X years in the glycosylated human its we the

intensive Hemopurifier the they're open Subjects feasibility the XXXX, in to On up diagnosis to enroll was XX, disease, have unit FDA for the to viral and an study have for Hemopurifier subjects established testing June will the be of supplement laboratory care in in IDE admitted will COVID-XX, the to in allow with That among a up a XX patients and/or ICU designed other centers SARS-CoV-X/COVID-XX or lung to acute our XX life-threatening disease study. injury at or to new as U.S. of a locally approved severe known criteria.

their Hospitals, approval, in clinical Irvine, and trial as for Hoag well IRB case Irvine have Memorial and this safety, Linda clinical in Hospital This for Loma enrollment. thirdly, for patient in received received reduction have sites as Hoag open to initial points California, in in -- to Loma are circulating virus and End California Linda, include Beach include agreements, preparing study, Presbyterian outcomes. Hospital completed and trial the will have Newport this addition -- of in Hospital Hold

This and Whole is Protein, with Cartridge Lectin-Affinity a case in after regulations, step with use Hemopurifier, patients Spike with COVID-XX treated Exosomal studies of manuscript these We Removal discussion patients microRNAs Infection. have the emergency Critically FDA, forward. Ill the covering the X -- entitled: Hemopurifier. treatments we single-patient published with Virus, with COVID-XX Under COVID-XX these Exosomes recently a by major reviewing

X ill of in the X of manuscript sessions a use the patients. The for COVID-XX Hemopurifier total critically describes

entry study coagulopathy, to assets injury, entry in hospital case at positive first complications with we And demonstrated the The that demonstrated exosomes was of patient's and have demonstrated cycle, the removal, The the was from XX. at improvement patient the ventilator weaned strong tissue treatments the patient's and suggesting received to lung the viremia was discharged day a significant our inflammation from the having and previously X viremia to who associated hospital. by time recovery. despite case, disease patient started in COVID-XX early contributed Hemopurifier treatment patient the COVID-XX the in without the SARS-CoV eventually

maybe and local The patient patient. X-hour infected placed believe the was and replacement a an the being start removal the second of of running vivo the on at advanced mortality in patient we hemopurifier from hours This continuous because demonstrated complications after completed trial. first subsequently on the without therapy expired bloodstream treatment virus by of X the patient disease placed the stage of hospital. The predictive renal the what ultimately X% of patient's CRRT SARS-CoV-X

In net June of our $XX.X million registered direct exercise we a $XX.X million of $XXX,XXX In in of proceeds the financing cash raised XXXX. from and and we approximately $X.X raised agreement. June approximately in ATM then million outstanding net proceeds XXXX, aggregate, approximately under through warrants. sales

for Jim to then I'll up to discussion, open back that, questions. turn the and it financial With

James Frakes

Chuck, Thanks, again, good and everyone. afternoon,

of commissions of a we And exercises cash before the approximately ATM million price the outstanding agreement it raised $XX.X in sales Following mentioned, an registered share then share some to to million $X.XX we've direct price at under the proceeds share and raised you fees up approximately based per and proceeds. York warrants. approximately the on raised June, was received $XX.X prices wanted financing at. give $X.X as Again, raised in and New on a came net our through Chuck's we color commentary Chuck commissions was we I million that institutional per in money Breaking in fees. investor City. before per of in funds down, on $XXX,XXX through net also $X

At cash had March $X.X we approximately million. of XX, XXXX, a balance

this the trials including million we us $XX.X manufacturing position, for cash very current well month, our up and raised earlier Hemopurifier. Our of clinical our conducting sets

expenses for Our $X.X the consolidated compared to fiscal fiscal of approximately year ended an XX, the approximately million million were ended XX, year That $X.X XXXX, March increase $X for approximately million. operating was March XXXX.

expenses professional increase million which $X was $X $X.X increases a related million were approximately and and in approximately million, partially of expenses decrease approximately offset That fees. due in in payroll to and administrative $XXX,XXX general by of of

and in was due the cash-based And March expenses compensation an ended of $XXX,XXX in for to that, ended XXXX, in a partially increase March year our another increase trial XX, increase supplies. $X.X of $XXX,XXX our in payments XX, $XXX,XXX. administrative of by an fiscal arose our million million laboratory increased general $XXX,XXX to $X.X related in approximately expenses to severance our The fiscal stock-based in in payroll about accrual $X of and primarily which compensation from compensation decrease year cash-based was expenses Chief and The former XXXX, Officer. million, and related our clinical Executive increases offset

fees, fiscal $XXX,XXX of in $XXX,XXX year primarily by our in legal fees, $XXX,XXX ended fees were March fees. scientific and the in which accounting $XXX,XXX the XX, in consulting fees in decrease And increases professional recruiting $XXX,XXX of arose and approximately partially in from decreases XXXX, offset

XX, ended year Health, fiscal in March $XXX,XXX nominal And in fiscal XXXX. Our ended of revenue $XXX,XXX fiscal the year compared Institute. in government are National during the other recorded the government Institutes in approximately expense XX, March XX, approximately was contracts year in XXXX. Cancer with XXXX, March National the contract we particular, the ended to The

commentary annual release XX, the As $X.X of million statements ended and interest before I our sheet that Form March file of earnings XXXX, and for for expenses results and this to XXXX, approximately our issued XXXX. related following on We these fiscal ended earlier included approximately March XXXX year million result noted, the XX, the periods and our for XX, will ending and for we the revenues fiscal afternoon. operations year-end a release loss increased XX, from changes fiscal in this report the the $X.X That noncontrolling call. balance just XXXX, in included year March XX-K press March

call August XXXX. early ended of will report XX, June with quarterly the next July coincide late the earnings our filing quarter or for in fiscal first on Our Form XX-Q

And open and please happy any I take now the call Chuck Operator, be questions would to that have. may questions. for you

Operator

[Operator from first Our Zacks. Marin is with Instructions] Marla question

Marla Marin

trials update now you right us clinical the conducted? are on I'm wondering currently that being some can if give

Charles Fisher

all present and are Newport completed a Linda, to took Chuck. it near we now. of need Beach X have are very Hoag we enrolling bit finished is We're an is X is the This approvals which they things. logistics, area are little of in IRB things with close their and internal Where Irvine, the but hospitals, and X in at have all and and for with nearly up Loma setting they patients do their us them,

getting than side a while. that feels we for that the COVID-XX we're be it into the So longer to on in taken far space wanted anticipated. of we It's had

of been the big and there challenges enrolling new into space much run and surge that of that new hospitals a COVID-XX One for not patients. have was left has the trials patients,

hit oncology thing well in So positioned forward same The patients. we're now for to hospital true was the oncology we're trials, hoping therefore fairly and strong the COVID by cannot the move oncology quickly because areas. that these be would enroll

present. are all start with hospitals for enrolling they're the each where we a they that's to at that where talked involved can feel we're space So and into We've background actively moving they the of patients.

Marla Marin

or based oncology we KEYTRUDA an in what then an for use terms when And around Okay. there there whether extended announcement time, on time for an we -- approved additional see provide specifically. are color KEYTRUDA? some been study, has use. about that to for Hemopurifier the of From you takeaways any read Can the

Charles Fisher

run results X of also KEYTRUDA that that using we've companies that. set make treatments, this as oncologist KEYTRUDA. of past at, number what some on depending is It may way look by is questions the teach we've but with longer of in individual and be patients after answered the up process first that's those there increase upon discussion a then the the decisions. the in look a Hemopurifier patients, week. overall trials recently been at it the trial as Hemopurifier One to None will us pharma we the the the about interest have take might a of had the to definitively, decision side The an

Operator

Wainwright. Next Vernon question Bernardino with is H.C. from

Vernon Bernardino

both was Jim, case in X same case X the the in way I the used between but Was there progress. used vivo X was the case release, with patients? press congrats the thought difference removal, that the Hemopurifier mentioned Hemopurifier the on any the and way. in You in

Charles Fisher

So day treat and that XX, contacted she in you're was, had in when I day evaluate your thought. a positive case chose basic mentioned and The not XX her, day and we viral was asked to at were difference correct X to when her beyond X, her been patient up but of illness. She patient then. to

particular inflammation viral and/or cancer not positive of SARS-CoV-X. her she viral levels in actively are circulating was exosomes, and/or high carrying for case, with So had loads. which she Alternatively, associated

demonstrated in significant her oxygen failure, requirements other the a So to actually improvement vasoactive for on we removed was her she within over her die -- number days her that, for virus X and were found or treated exosomes. and X quite in ill, in she she and And means notes hours. in XX respiratory chart we near hours what her, that No had particles her failures. profoundly learned was for a and X of organ would dramatic X term

us is role in ongoing teaches that in patients. play significant that What a these the exosomes the process

a smoothly, have we XX% we patient, that viral who had of profound worth, disease viral second XX the X years reduce during of onset, exosomes, SARS-CoV-X, dramatically removal him, circulating that's days' X-hour since sorry, so been was went of X improved. And rated patient or cardiovascular had his new actually And childhood exome and old, at load. the treated, his were first -- in and half able mortality, the had he was to levels high more than very by which very about treatment

if time, So same time. agents imagine And -- presence an what's the of at them. at that what's present it's when remove we both the will treat it's issue of finally we we a both same were present

Vernon Bernardino

for COVID-XX admitted Now the case patient X was pneumonia.

So exactly, was as known what you I therefore, admitted? paper the I'm sorry, but exactly she time the show not said, but don't at to the was it viral was remember status

Charles Fisher

it viral long which as X We up had the viral swabs, that's many days, as circulating at she causes it active high the very load the of had fibers and between removed my picked She At but load her first virus cetera. off dramatically. was issues. In and active the XX. some somewhere when head, point, I XX and much, as viral starts but specifics it circulate that perhaps remember Absolutely. measle days of for doesn't it goes et those day don't positive huge she at we diminishing improved exosomes. her point, no but and XX, circulating and still exosomes intracellular, amounts case, top

Vernon Bernardino

sites are cases, there exosome, Yes, for for what Hemopurifier queue. for the for the me expectation that get in Hemopurifier just in activity trial and surge With states? plans like question so having exciting. back now unfortunately, before and in these clinical States targeting, Last of any the United a geographies, looks in the I unvaccinated the

Charles Fisher

basis is gave and the is enrolling watch standard so patients are daily they the where that be are. us to other We're FDA centers, where we that patients. possible, patients and centers occurring same centers as as trying the quickly to XX interested would gave those What be do they we're talk trying in to to on can XX the a which outbreaks

The not do of the the what's at variants but play can may time implied that asked and different regarding is we other your we a there. the is directly, And role have variants. role we question, that the information share thing in

Vernon Bernardino

as definitely interest a Hemopurifier as Yes, in evaluation sites. these far growing see can I

Operator

question is Anthony Next with Vendetti Group. Maxim from

Anthony Vendetti

these and Jim, doing? your So for Chuck are you of on Hey X study feasibility patients are COVID, correct? the X how first early

Charles Fisher

These X patients are actually in protocol. an use emergency

physician just authorization, use say Or other now physician authorization. meaning the would very under other has emergency no have with patients involved with the been you use use, the can therapy. emergency the not enrolled have a emergency request attending to we emergency discussed consult also by we by those of worked an use, and Both no the equally is out specific which protocol. patient via were is can therapy, we FDA, be there qualified So who with were not there the made and an with as

James Frakes

Not the clinical trial.

Charles Fisher

not clinical trial. And the

Anthony Vendetti

right Is to But do COVID Right. that correct? you study authorization up an for an early XX now, patients. enroll have feasibility to

Charles Fisher

absolutely That's correct. Yes.

Anthony Vendetti

find many to patients you how Can on and correct criteria. you update that update XX-patient us give that's to to looking? -- I fit I an How sites? us give you Can Okay. switch you XX- expect -- And give the there? know KEYTRUDA, obviously a of know an have to Can you have enrollment next the on patient us idea then also, you the EFS. to an that's when

Charles Fisher

to passed earlier the So have protocol ready X FDA. that we are with we have of go and X -- that to training. as have mentioned hospitals I the Hoag have relates the their IRB it finished and their

Linda them. evolving very Those very our because leaders to early patients, and on through good they is X in So all be are position. quickly closely they see are Loma enroll. on, came ready as they training should behind

also see but around those where know, the So other you country. as this be a in basis, enrolling if probably we would to actively places watch different bounces first, disease the expect daily on geographies. And news the sites you we're

the it approved the is protocols, by use we disease the to So emergency approved protocol or be want the with the time at hits the where whether FDA.

Anthony Vendetti

certain it's you you which access out to for the the which you hold there's Delta terms cases feel U.S. feel, Chuck, seeing easier you're version professional Delta and go like seem from time, that in unfortunately, a these But opinion there? according fall, your be to up going taking professional variant, summer of the a are do even the do another the particularly, that just California, physician, point in at variant. feel here to what whether this to But variants in maybe And in what's -- do you. or cases you opinion, of mean could and as your do feel

Charles Fisher

severe? who at variant it cases it lean Or probably less What physicians probably reading bit the more deaths? to is have early mixed rapid taken a had more and somewhat towards on -- is the uptick on, patients. there's I'd of countries a seeing the And is of has little particular It's it in infecting that's in part. the very the but this severe causing severe, and then started where we're more least talking fairly care my literature speculation ones.

take In we we increasing vaccination terms primarily population we'll we States, increasing though have even of been have. have population. the for if United -- -- America impact North instance, that an What

that presumably, we know the mentioned, will it this contained what we have. be the not you that role. play one by vaccinations So But don't well completely that particularly some may variants, is

perspective, we've all with And intent them. an our any at understanding roles of and not early treated play since comment with the so too It's role to we from their we them. of may what are see looking variants actively,

Anthony Vendetti

understood. to prognosis That's Can more -- What's uptick have slower of second the where of Do identified with but No, us an just the you only in patients Are you'll feel a What's XX like -- a year? know then before you? XX need are Okay. give KEYTRUDA. combination end enrollment, your patients. terms helpful. couple you the patient? there? of sort you treatment your best have that the -- update, that's you slower you I And

Charles Fisher

at our some University local very Center. think been side good on Medical resolved. the of of Well, and we had recently And logistics Pittsburg I a with discussion the have intense colleagues either

patients. more seeing anticipate would we So

been open KEYTRUDA were they At of had the enrolling now wave, that, primarily cancer up the other open of wave their a kind hospital, had COVID-XX and were they for not for for had on used the by Hemopurifier that a culture time because to bit and threw early that them SARS-CoV-X, being hit first finally not first they're trial. ready purpose. challenges they COVID we're plus beds their patients the of off their One they was patients, but for

have So would internally. creative they we ones were to patients get talked through referred could been also get the that them where they that. who normally in looking outside very They

We we're and very working their with have collaborative for a leadership. program them, including top that,

of patients life these hospital internal We're be with beginning to think everybody can their such events numbers that own either their in they back the other identify role hospitals there. or track I able year. So a on recognizes played optimistic will we that that at of complex, that the said the referral we've get

Anthony Vendetti

of a particularly UPMC But obviously said there for number X Pittsburg Center those, Center directly you could or either it center, of you're Sure. University Medical programs. it University of indirectly? Medical world-renowned and is be is center of top the but through with currently? working there's Or oncology, or the that referral ones. of a that with directly them X Is is another Pittsburg

Charles Fisher

trial referral primary which the portion, go for would standard the the the brought to care. on large single University consented idea of it's If base. own, have had center back for hospital a a for KEYTRUDA can since they the and patients Pittsburgh and No, trial the they their in trial, Pittsburgh be that will treatment, for floated to of they could got be appropriate be their they Hemopurifier

approval idea was and side creative that to their on of the So help increase patients. and unique a try

Anthony Vendetti

the exists. reason. or helpful. seems lastly, ability for one has virus on of part for implications good it your road? the if That's broadly, in that this Is these for now, then first on pathogens just And obviously, that is currently have the the your the clear were view BFS X it focusing positive the comes What's patients on pathogens it back opinion of use? COVID as Hemopurifier XX emergency Great. either could come other back other or other Okay. the down to like you're But broad viruses terms the

Charles Fisher

laboratories that anything that's reconstructed viruses. the cetera all Everyone in Well, a by hands it's or with tested, CDC or Hemopurifier. some virus has national USAMRAA tested the et it we or years that a know glycosylated hands pathogenic we and -- back sugar including motif our of in on and our bind we've we'll that the bind, that was XXXX the virus, whether [indiscernible]

So generally good. if of very bind likelihood virus, ability there's is the a our glycosylated to it

for of we'll what at to and because we for we've be there to others we've on on can't. It reach keep percent pandemic a I tested, in them ones continue in want our that that spike for report, is started ongoing be all way we've a this broader quite bind. an something of we been like probably make significant to things we viruses bind that a as may that least large statement. via bit. and massive real learning, basis, don't the we of think that would number role far, us, protein vary that soon The those It's which as part types so The becomes, But question that as a And and much health area. global too basis might future, probably little be be in learn future our should that the a in hard part setting, certain can SARS-CoV-X given seeing is to may general changing have motif the care. from now generally a antibodies

able test an all to stop take of cases, role and for were to have will these We role. see I ongoing before there But they And would severe out the a the try way to first. would if kind we pandemics be I more loose. that break having think be them us then us

Anthony Vendetti

weigh to as on more just Okay. Chuck, well. Jim, maybe, this but free is Great. And in this for feel

anything increased raises, you're of of working to recent much on, really you expedite them? you're are enroll considering at or to centers capital flexibility any that these capital the these there raises, to has programs? that that you expedite with of any given Is going mercy programs the has forward? pretty the the working more anything been Or With

James Frakes

got a to more it's supervise positives. think couple the I on people treatments. of We hire can the call senior hospitals and Well, then Right.

in So solid, that. experienced, we're thinking some to very of do bringing good people

a count we believe. need a the small would to supervise treatments multiple and that that. We been to head difficult country, we do had such it hope be have to in So across and we position

efforts have our back trials. can Hemopurifiers to the while keep we step manufacturing up we We enough step to Secondly, manufacturing up for with clinical to deal success. need

we're manufacturing So investigating that up steps really take to and efforts. in-house some step our

I in So ways, see direct a correlation. those

Operator

question next Dave from is The Lavigne with Trickle Research.

David Lavigne

So think I don't -- just want this. I to -- think I I misunderstood

is original that you X Is patient patient right? actually some that prior in briefly the kind of So discussed calls, right?

Charles Fisher

Yes. the was a we worked, a with variety cured to cleared go in clearing those by fact, at My such have virus. she of the we so it there -- at earlier actually circulating well, she has she and and cleared was, clearly likelihood exosomes, disease At and by and the point basically to inflammatory is, no an and asked -- her home. able that that very and which, her known much to get been after failure, had she moribund. did. disease tried exosomes level And is thought big a That are after circulating might time that a high exosomes, organ bind with was things were in I then have discussion use patient on, emergency point, she was SARS-CoV-X had Anthony And see she early nothing has of as high virus patient. she mentioned point

David Lavigne

that may trial trial particularly sort understanding that in between have point, the have who loads end instance. it's that So or viral advanced patients, in maybe X have, the will difference -- the I I'm guess for possible the are don't you the that don't high maybe at of they if up people enough

going trial but front collect sort right? it's how capture also sort -- to reduced seems focused here, load, I'm and at is look looking of end, things viral I'm little still the so load, same information. the going exosome And bit going the at to that mean look We're but sort as center assuming well, viral a -- the it and on exosome we're right? but of and of it to like at in thing that still I we're

Charles Fisher

Well, pursuing oncology play major inflammation and the role it indication. and cancer in a the advancing we're why that's exosomes in

in think what been over learning by circulating -- -- those that diminishing. usually, XX, that day diminishes the also, and I they're we're learning viral in circulating have others X loads, time load have the has to viral

And so there's as they circulating virus have much a body, It doesn't probably not the of load. mostly in don't it's viral but intracellular. mean

Alternatively, that exosomes. currently we're unique taking group both, patients we're significant of since will binding And out have a beginning. position circulating same the of either in it at

first are. very patients with instance, it if the us the virus, we be FDA us to put For if of ill circulating kind gave -- would in was opportunity role. probably decrease to treatment a significant gave What this they turned treated went treat and before we we around. that's she particular ill By the her. of failure, profoundly were she able in the patient, her where was through And multi-organ actually to we start that time

there virus a playing in is not role dynamic we the that that understanding ignore. a that's there's should just the an think together I early just and exosome So becoming

David Lavigne

Okay.

know, who some be then may will there in them come. where have of that really of we further Is terms of right? kind So these don't -- they take patients going obviously, are be along right? others. I And as that what to mean than progression, to you're kind

Charles Fisher

inflammatory associated novel assess with it's exosomes, fit It's IP. pacing and/or ability degree, exosomes or further in, are that's parts right we to to whether hand in actually our certain virus suddenly but to a all a ongoing work

Operator

like closing any remarks. back the Dr. conference to would I for session. turn over question-and-answer our concludes This Fisher to

Charles Fisher

the like We'd Gary. excellent Thank surge you, had to a everybody of questions. thank call joined today. who We

a the diseases As some us We you coming appreciate more think that interface. more us and interest, of and your like. in see disease terms at get to fairly to personnel, hope to you'll and you've scientific continue very because that since time November seen, desperate you now follow roughly group and things I from made of ability capability changes significant capability, or we've really we

Operator

The conference presentation. today's has attending for concluded. Thank you now

You may disconnect. now

Aethlon Medical (AEMD) 24 Jun 212021 Q4 Earnings call transcript